Skip to contentS
Syndax Pharmaceuticals Inc
S
SNDXSyndax Pharmaceuticals Inc Q3 2020 · 10-Q
Revenue$379.00K$379.00K±0.0% vs Q3 2019 Net Income-$20.44M-$20.44MN/M vs Q3 2019 EPS Diluted-$0.46-$0.46N/M vs Q3 2019 Operating Income-$19,853,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Syndax Pharmaceuticals Inc · CIK 1395937 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-5238.3%−1768.9 pt vs Q3 2019
Net margin-5392.3%−2007.4 pt vs Q3 2019
ended Sep 30, 2020 · filed Nov 5, 2020 · 36 d after period end